Episódios
-
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss how labs can enhance patient access to improve health equity.
Specific topics of discussion include:
Innovations creating new possibilities, such as mobile clinics, at-home tests, and artificial intelligence.The responsibility of laboratory professionals to help guide the use of these new tools and the importance of collaboration between health systems.What’s needed to make solutions scalable and sustainable.Learn more in Dr. Morice’s “Lab Manager” article.
-
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by genetic counselors Carrie Lahner, M.S., CGC, and April Studinski Jones, M.S., CGC, to discuss how family medical history can inform genetic testing strategies.
Specific topics of discussion include:
The seven main types of genetic testing, and how clinicians know when and what genetic testing to order.Key family history details to collect to inform decisions about genetic testing. How genetic counselors collaborate with physicians and laboratorians to make testing decisions. Recent genetic testing advancements that are improving diagnostics. -
Estão a faltar episódios?
-
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
Speaker 3: (00:32)
Could you give us a brief overview about your background and yourself?Speaker 3: (02:16)
Could you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan?Speaker 3: (05:34)
What specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories?Speaker 3: (08:01)
Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate?Speaker 3: (10:36)
Could you elaborate on the specific clinical indications for testing in relation to irinotecan?
Speaker 3: (13:27)
How do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results?Speaker 3: (14:02)
Are there any other factors or related genes that should be considered alongside UGT1A1, particularly for cancer therapy? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent outbreaks in vaccine-preventable diseases.
Specific topics of discussion include:
Recent increases in outbreaks of infectious diseases, such as pertussis, measles, and polio. The serious side effects of the diseases. What’s fueling the resurgence of these diseases.Testing options for infectious diseases and resources for physicians. -
While confirmed cases for many respiratory illnesses are currently low, they will almost certainly spread as we move further into fall and winter. Now is the perfect time to prepare and take steps to protect yourself from everything from COVID-19 and influenza to RSV and the common cold.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss practical steps for protecting yourself and innovations that are making testing and vaccination easier.
Specific topics of discussion include:
The importance of vaccinations and preventive measures to keep you healthy. Innovations that are making it possible to provide more at-home options for vaccination and testing and when these options will be most beneficial. The latest status on avian influenza. -
Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases patients' risk for many kinds of cancer.
Speaker 3: (00:32)
Could you provide our listeners with a little bit about yourself and your background?Speaker 3: (01:27)
Could you give an overview of our MLH1 hypermethylation, also referred to as MLHPB in our test catalog?Speaker 3: (02:48)
Can you talk about why your team thought it was really important to develop this test?Speaker 3: (04:03)
What patients would this testing really benefit?Speaker 3: (06:10)
How are the results used in patient care?
Speaker 3: (07:56)
Anything else you would like our listeners to hear about MLHPB? -
From cyberattacks to utility failures, technology disruptions are a growing risk in an increasingly digitized and automated laboratory environment. Planning for technology disruptions positions laboratories to embrace the full power of automation, artificial intelligence, and digitization while still meeting critical patient care needs during an outage.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by John Osborn, operations administrator in the Department of Laboratory Medicine and Pathology at Mayo Clinic, who helps lead efforts to prepare for technology disruptions in the laboratory.
Specific topics of discussion include:
Immediate considerations when a technology disruption occurs and prioritizing the restoration of systems and processes. How to create strategies and tools to guide decision-making and operations amid multiple outage scenarios. Lessons learned from real life examples, including the importance of clear communication, empowering lab directors to make decisions, and pre-planning for recovery. Preventive measures and risk mitigation strategies you can take today to make it easier to respond during a future incident. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Alicia Algeciras-Schimnich, Ph.D., a professor of laboratory medicine and pathology at Mayo Clinic and co-director of the Clinical Immunoassay Laboratory. They discuss Mayo Clinic’s plasma test for detecting Alzheimer’s disease and how it supports increased access and early detection.
Specific topics of discussion include:
The phospho-Tau 217 plasma test (Mayo ID: PT217) used to evaluate individuals aged 50 years and older with symptoms of cognitive impairment who are being assessed for Alzheimer’s disease and other causes of cognitive decline.The benefits of a blood test versus the other diagnostic methods for Alzheimer’s disease.Why early diagnosis is so important for quality of life and treatment planning.How tests like Mayo Clinic Laboratories’ PT217 may change the landscape of Alzheimer's research and treatment. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Dong Chen, M.D., Ph.D., chair of the Division of Hematopathology in the Department of Laboratory Medicine and Pathology at Mayo Clinic. They discuss rare and inherited platelet disorders and esoteric laboratory testing of hematologic disorders.
Specific topics of discussion include:
How these rare disorders are diagnosed through laboratory tests.Why platelet transmission electron microscopy is considered the gold standard for diagnosing disorders like Hermansky Pudlak syndrome, Wiskott-Aldrich syndrome, Chediak Higashi syndrome, and Jacobson/Paris-Trousseau syndrome.The process involved with developing and validating the PTEM test (Mayo ID: PTEM) at Mayo Clinic.The importance of ongoing research and advocacy to enhance care for patients with rare platelet disorders. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the latest news in pathogen activity and how these viruses serve as an important reminder of the role of the public-private lab partnership.
Their discussion includes:
How the United States addresses emerging pathogens and the importance of a partnership between public health laboratories and private or clinical laboratories.Why access to testing is vital to prevent pathogen outbreaks and pandemics.The need for an effective legal framework around pandemic and hazard preparedness.Current diagnostic efforts around mpox, bird flu, and COVID-19, and opportunities to expand at-home testing. -
Matthew Schultz, Ph.D., and Amy White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.
(00:31)
Would you share a little bit about yourself and your background?(01:11)
Could you provide us with an overview of this particular peripheral neuropathy?(03:09)
Can you share the background as to how your team learned about this condition and how you considered testing for it?(04:42)
Would you explain what you saw when you performed the urine test on the first patient?
(05:26)
Were you able to test additional patients with this condition?(06:09)
Could you expand on why this urine test is important?
(07:20)
How does a health care provider order urine testing for SORD deficiency?(07:59)
How does this new SORD urine test complement the existing Mayo Clinic Laboratories test menu?(08:55)
Could you summarize the benefits of ordering this SORD urine test at Mayo?
-
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guest Donald Thomas, M.D., a rheumatologist and lupus researcher. They discuss how Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, is enhancing the care and quality of life for patients affected by systemic lupus erythematosus (SLE).
Their discussion includes:
Symptoms of lupus and characteristics of the complex disease process.The role of laboratory testing in diagnosing and managing long-term treatment for patients with lupus.Dr. Thomas’ clinical experience using the Progentec aiSLE® DX Lupus Flare Risk Index and Lupus Disease Activity Index for his patients, and how these tests have enhanced collaborative treatment planning.Why these novel tests are a major step forward in expanding diagnostic tools and improving care for patients living with SLE. -
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.
Show notes
Speaker 3: (00:32)
Would you provide a little background on yourself, Dr. Mills?Speaker 3: (01:19)
Dr. Dubey?Speaker 3: (02:07)
Can you give a brief overview of our demyelinating test and recommended use?Speaker 3: (03:52)
Can you discuss how this new test will assist in a patient's journey?Speaker 3: (05:46)
Can you tell us some of the unique features of this test?Speaker 3: (08:09)
Dr. Dubey, as a neurologist, how does this test set us apart in the market?Speaker 3: (11:05)
Could you summarize the benefits of having both a demyelinating panel and an axonal panel?Speaker 3: (11:40)
Why should a patient have an axonal or demyelinating test versus a sensory and motor test for peripheral neuropathy? -
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guests Bernard Rubin, D.O., MPH, chief medical officer of Progentec Diagnostics, and Melissa Munroe, M.D., Ph.D., chief scientific officer and principal investigator of Progentec Diagnostics. They discuss Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, for patients affected by systemic lupus erythematosus (SLE).
Their discussion includes:
The Progentec aiSLE® DX Lupus Flare Risk Index that uses an algorithm to calculate a flare risk index, which assigns a score based on a patient's risk of a forthcoming lupus flare.The Progentec aiSLE® DX Lupus Disease Activity Index that characterizes a patient’s current disease activity into low, moderate, or active states.How these two tests were developed and for whom they are recommended.Why these tests are a significant development and how they enhance the quality of life for patients living with SLE. -
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.
Speaker 3: (00:32)
Would you tell us a little bit about yourself and your history with this testing?Speaker 3: (01:25)
Would you tell us a little more about this assay?Speaker 3: (04:57)
Which patients should have this testing and when should it be performed?Speaker 3: (05:30)
What alternative tests exist and how do they compare?Speaker 3: (06:28)
How are the results used in patient care? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest advancements in Alzheimer’s disease testing and treatment.
Their discussion includes:
Why there is an increased focus on Alzheimer’s disease in the diagnostics industry.The development of groundbreaking blood tests that can detect Alzheimer’s-related biomarkers.The importance of accurate testing to avoid false positives.The role of laboratory scientists in guiding appropriate test usage.The promising new treatment options and the need for informed decision-making in a patient’s healthcare journey. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They cover current trends, pain points, and opportunities for growth in the lab and diagnostics market.
Their discussion includes:
Insights from Dr. Morice’s participation in an Advisory Board webinar about 2024 lab market trends.Why there is an increased demand for laboratory testing.The opportunities that come with digital pathology, at-home testing, and remote diagnostics. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic. They discuss the upsurge of mpox cases, particularly in Africa, and why the World Health Organization has declared it a public health emergency of international concern.
Specific topics of discussion include:
Background information on the monkeypox virus, and the current outbreak situation.What is contributing to the rapid spread of mpox in the Democratic Republic of the Congo and neighboring countries.How the current mpox outbreak compares to the global outbreak in 2022, and lessons learned that could be applied today.Testing options for diagnosing mpox.What can be done to control the spread of mpox and prevent future outbreaks. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss what’s new and ongoing with pathogens and infections.
Their discussion includes:
Summer cases of COVID-19.H5N1 (avian influenza) activity and testing options.Increasing dengue fever infections.Outbreaks of listeria and cyclospora.The importance of public-private partnerships in preventing disease outbreaks and increasing access to testing. -
Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.
Speaker 4: (00:32)
Please give the audience a little information about yourself and your background.Speaker 4: (02:12)
Please give the audience a brief overview of this assay.Speaker 4: (04:34)
Which patients should have this testing and when should it be performed?Speaker 4: (05:50)
What alternative testing options are available and how do these compare?Speaker 4: (06:47)
How are the results used in patient care? - Mostrar mais
